Principal Financial Group Inc. reduced its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 16.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 89,719 shares of the company’s stock after selling 17,697 shares during the period. Principal Financial Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,617,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in TEVA. Renaissance Technologies LLC grew its holdings in shares of Teva Pharmaceutical Industries by 13.4% during the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock worth $141,839,000 after buying an additional 1,031,400 shares in the last quarter. Truist Financial Corp grew its stake in Teva Pharmaceutical Industries by 7.0% during the 2nd quarter. Truist Financial Corp now owns 3,885,251 shares of the company’s stock valued at $63,135,000 after acquiring an additional 254,483 shares in the last quarter. National Pension Service raised its holdings in Teva Pharmaceutical Industries by 107.3% in the 3rd quarter. National Pension Service now owns 3,170,640 shares of the company’s stock valued at $57,135,000 after acquiring an additional 1,640,940 shares during the last quarter. Iron Triangle Partners LP lifted its stake in Teva Pharmaceutical Industries by 113.1% in the 1st quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock worth $39,083,000 after purchasing an additional 1,469,864 shares in the last quarter. Finally, Tri Locum Partners LP boosted its holdings in shares of Teva Pharmaceutical Industries by 15.1% during the 2nd quarter. Tri Locum Partners LP now owns 2,550,307 shares of the company’s stock worth $41,442,000 after purchasing an additional 334,119 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.
Teva Pharmaceutical Industries Stock Up 0.2 %
Shares of NYSE:TEVA opened at $17.12 on Friday. The company has a market capitalization of $19.40 billion, a price-to-earnings ratio of -20.14, a PEG ratio of 1.33 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a 12-month low of $9.35 and a 12-month high of $19.31. The business has a 50-day moving average price of $17.67 and a 200 day moving average price of $17.32. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57.
Analysts Set New Price Targets
Read Our Latest Research Report on TEVA
Insiders Place Their Bets
In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.55% of the stock is currently owned by insiders.
Teva Pharmaceutical Industries Profile
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Featured Articles
- Five stocks we like better than Teva Pharmaceutical Industries
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- MarketBeat Week in Review – 11/18 – 11/22
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.